NewLimit Series B

NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a "lab in a loop" system where AI models predict and experiments validate therapeutic candidates.